Tech Company Financing Transactions
Excalipoint Therapeutics Funding Round
5Y Capital, Centurium Capital and Co-win Healthcare Fund joined a $68.7 million Seed funding round for Excalipoint Therapeutics. This venture round was announced on 3/18/2026.
Transaction Overview
Company Name
Announced On
3/18/2026
Transaction Type
Venture Equity
Amount
$68,700,000
Round
Seed
Investors
Proceeds Purpose
The company intends to use the funds to support advancement of its proprietary technology platforms and pipeline of differentiated T-cell engager programs.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Li Yuan (No. 668 Xinzhai Road), Jing'an District 1709
Shanghai, Undisclosed
China
Shanghai, Undisclosed
China
Phone
Undisclosed
Website
Email Address
Overview
Excalipoint Therapeutics is a clinical-stage biotechnology company dedicated to the discovery and development of next-generation innovative T-cell engager (TCE) therapies to address unmet medical needs globally. Centered on multiple proprietary TCE technology platforms, including TOPAbody Platform, T-Cell Immune Shield Platform and TCE Probody Platform, the company is committed to developing novel T-cell based therapeutics with greater differentiation and stronger clinical potential to overcome treatment barriers of existing therapies. With six pipeline programs across oncology and immunology, its lead candidate EXP011(CTM012) is in Phase I/II trials for solid tumors.
Management Team
Browse more venture capital transactions:
Prev: 3/18/2026: CocoonCarbon venture capital transaction
Next: 3/18/2026: Obin AI venture capital transaction
Share this article
Where The Data Comes From
We do our best to document funding rounds that are announced publicly. VC investment data records reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs








